|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||11.36 - 11.82|
|52 Week Range||5.42 - 15.08|
|Beta (3Y Monthly)||2.02|
|PE Ratio (TTM)||34.06|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.90|
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018. The offering was being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on April 28, 2016.
Comparable sales were down 0.6 percent, while analysts expected a 0.3 percent increase. Kimbell Royalty Partners KRP stock dipped almost 6 percent in the extended session after the company announced a public offering of 3 million shares of common stock. ChemoCentryx CCXI shares fell as much as 12 percent in after-hours trading following an announcement that the biopharmaceutical company has commenced a public offering of $75 million worth of common stock.
ChemoCentryx, Inc. (CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold. J.P. Morgan and Piper Jaffray & Co. are acting as joint book-running managers for the offering. All shares of the common stock to be sold in the offering will be offered by ChemoCentryx. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
MOUNTAIN VIEW, Calif., Sept. 26, 2018-- ChemoCentryx, Inc.,, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare ...
Vifor Pharma Group acquires an additional 7,343,492 common shares of ChemoCentryx, Inc. (CCXI) from GlaxoSmithKline - an additional 14.6% stake in the company. As a result Vifor Pharma Group will hold a total of 21.2% of ChemoCentryx on completion of the transaction. The increased investment follows the establishment of a partnership with ChemoCentryx, which began in May 2016.
MOUNTAIN VIEW, Calif., Aug. 28, 2018-- ChemoCentryx, Inc.,, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September:. ...
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ferroglobe ...
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -27.27% and -11.02%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Mountain View, California-based company said it had a loss of 14 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
--Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis--. --Ongoing clinical trials with avacopan in C3 Glomerulopathy and CCX140 in Focal Segmental Glomerulosclerosis, ...
MOUNTAIN VIEW, Calif., Aug. 02, 2018-- ChemoCentryx, Inc.,, today announced that the Company's second quarter 2018 financial results will be released after market close on Thursday, August 9, 2018. ChemoCentryx ...
Johnson & Johnson (JNJ) has been ordered to pay $4.69 billion in damages to 22 families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.
Jazz Pharmaceuticals (JAZZ) signs a definitive contract to sell its Prialt rights to TerSera Therapeutics for a settled amount of $80 million in cash upon its closure.
Zacks.com featured highlights include: Weight Watchers, Johnson Outdoors, ChemoCentryx, Harte-Hanks and IEC
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ChemoCentryx, 58.com, Seagate, Garmin and Texas Instruments as Zacks Bull and Bear of the Day
Dodging all political ills, investors continued to pour money into the fast-growing companies, pushing the Nasdaq Composite Index to new highs since Mar 13. The surge in the technology sector, which accounts for nearly half of the index, helped the Nasdaq’s northward journey. Notably, the trio of the group — Apple Inc. (NASDAQ:AAPL), Amazon.com, Inc. (NASDAQ:AMZN) and Microsoft Corporation (NASDAQ:MSFT) — set new milestones.